Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Journal for Immunotherapy of Cancer|December 20, 2017
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomasSamantha N Reiss, Prakirthi Yerram, Lisa Modelevsky, et al.Leukemia & Lymphoma|November 11, 2021
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center studySamantha N Reiss, Prakirthi Yerram, Lisa Modelevsky, et al.Journal of Neuro-Oncology|August 22, 2019
Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomasPrakirthi Yerram, Samantha N Reiss, Lisa Modelevsky, et al.CNS Oncology|September 18, 2018
Rapid infusion rituximab is well tolerated in patients with primary CNS lymphomaLisa Modelevsky, Richard Tizon, Samantha N Reiss, et al.Annals of Lymphoma|April 17, 2023
Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohortPrakirthi Yerram, Samantha N Reiss, Lisa Modelevsky, et al.Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.Pageof 1